Erratum: Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer (Proceedings of the National Academy of Sciences of the United States of America (2009) 106, 13 (5312-5317) DOI: 10.1073/pnas.0900827106);Characterizing the developmental pathways TTF-.1, NKX2-8, and PAX9 in lung cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 13, 2009, Pages 5312-5317

  Hsu, David S ^a,b   Acharya, Chaitanya R ^a   Balakumaran, Bala S ^a   Riedel, Richard F ^a,b   Kim, Mickey K ^a   Stevenson, Marvaretta ^a,b   Tuchman, Sascha ^a,b   Mukherjee, Sayan ^a   Barry, William ^a   Dressman, Holly K ^a   Nevins, Joseph R ^a,b   Powers, Scott ^c   Mu, David ^d   Potti, Anil ^a,b  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Cold Spring Harbor Laboratory ^*  (United States)

^d PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Gene expression; Lung cancer; Transcription factors

Indexed keywords

CISPLATIN; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NKX2.8; TRANSCRIPTION FACTOR PAX9; UNCLASSIFIED DRUG;

ARTICLE; CANCER RESISTANCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION;

EID: 65249131825     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1111196108     Document Type: Erratum

References (38)

1. Mullighan CG, et al. (2007) Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446:758-764.
2. Garraway LA, et al. (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436:117-122.
3. Weinstein IB (2002) Addiction to oncogenes-the Achilles heel of cancer. Science 297:63-64.
4. Garraway LA, Sellers WR (2006) Lineage dependency and lineage-survival oncogenes in human cancer. Nat Rev Cancer 6:593-602.
5. Kendall J, et al. (2007) Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc Natl Acad Sci USA 104:16663-16668.
6. Kwei KA, et al. (2008) Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene 27:3635-3640.
7. Peters H, Neubuser A, Kratochwil K, Balling R(1998) Pax9-deficient mice lack pharyngeal pouch derivatives and teeth and exhibit craniofacial and limb abnormalities. Genes Dev 12:2735-2747.
8. Tanaka H, et al. (2007) Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res 67:6007-6011.
9. Weir BA, et al. (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450:893-898.
10. Bild AH, et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439:353-357.
11. Chang JT, Nevins JR (2006) GATHER: a systems approach to interpreting genomic signatures. Bioinformatics 22:2926-2933.
12. Artavanis-Tsakonas S, Rand MD, Lake RJ (1999) Notch signaling: cell fate control and signal integration in development. Science 284:770-776.
13. Cormier S, Vandormael-Pournin S, Babinet C, Cohen-Tannoudji M (2004) Developmental expression of the Notch signaling pathway genes during mouse preimplantation development. Gene Expr Patterns 4:713-717.
14. Hogan BL (1996) Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev 10:1580-1594.
15. Nakasato M, et al. (2006) Involvement of the STAT5 signaling pathway in the regulation of mouse preimplantation development. Biol Reprod 75:508-517.
16. Cantrell DA (2001) Phosphoinositide 3-kinase signalling pathways. J Cell Sci 114:1439-1445.
17. Paliga AJ, Natale DR, Watson AJ (2005) p38 mitogen-activated protein kinase (MAPK) first regulates filamentous actin at the 8-16-cell stage during preimplantation development. Biol Cell 97:629-640.
18. Bejarano PA, et al. (1996) Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Mod Pathol 9:445-452.
19. Di Loreto C, et al. (1997) Immunocytochemical expression of tissue specific transcription factor-1 in lung carcinoma. J Clin Pathol 50:30-32.
20. Fabbro D, et al. (1996) TTF-1 gene expression in human lung tumours. Eur J Cancer 32A:512-517.
21. Khoor A, Whitsett JA, Stahlman MT, Olson SJ, Cagle PT (1999) Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. Hum Pathol 30:695-700.
22. Salgia R, Skarin AT (1998) Molecular abnormalities in lung cancer. J Clin Oncol 16:1207-1217.
23. Shigematsu H, et al. (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-346.
24. Sweet-Cordero A, et al. (2005) An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet 37:48-55.
25. Potti A, et al. (2006) A genomic strategy to refine prognosis in early-stage non-smallcell lung cancer. N Engl J Med 355:570-580.
26. Raponi M, et al. (2006) Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 66:7466-7472.
27. Schiller JH, et al. (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98.
28. Jemal A, et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43-66.
29. Golub TR, et al. (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286:531-537.
30. van de Vijver MJ, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009.
31. Dave SS, et al. (2006) Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 354:2431-2442.
32. Huang E, et al. (2003) Gene expression predictors of breast cancer outcomes. Lancet 361:1590-1596.
33. Barlesi F, et al. (2005) Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung. Br J Cancer 93:450-452.
34. Haque AK, Syed S, Lele SM, Freeman DH, Adegboyega PA (2002) Immunohistochemical study of thyroid transcription factor-1 and HER2/neu in non-small cell lung cancer: strong thyroid transcription factor-1 expression predicts better survival. Appl Immunohistochem Mol Morphol 10:103-109.
35. Beer DG, et al. (2002) Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8:816-824.
36. Lu Y, et al. (2006) A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med 3:e467.
37. Van Gelder RN, et al. (1990) Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci USA 87:1663-1667.
38. Hsu DS, et al. (2007) Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol 25:4350-4357.